01375nas a2200217   4500000000100000008004100001260001200042653001900054653001200073653001600085653001400101100001300115700001300128700001400141700001300155700001200168700001200180245012100192520083000313022001401143       2024                            d  c05/202410aClarithromycin10aleprosy10aMinocycline10aOfloxacin1 aSharma A1 aParkhi M1 aChhabra S1 aNarang T1 aHanda S1 aDogra S00aA challenging case of borderline lepromatous leprosy non-responsive to WHO-MDT: exploring approaches beyond WHO-MDT.3 a<p>Just as we prioritize personalized medicine for various other medical conditions, we should also include a neglected disease like leprosy, ensuring that patients receive the best care possible and improving their quality of life. Our case highlights the importance of instituting an alternate therapeutic regimen in a scenario where there is a lack of clinical response to multidrug therapy, even in the absence of documented drug resistance of the currently available molecular diagnostics. The search for the perfect regimen tailored for each individual leprosy patient should continue. Alternate anti-leprosy therapy is highly useful in cases with confirmed drug resistance or clinically non-responsive cases; however, their misuse should also be strictly avoided to prevent the development of resistance to them.</p>
  a1878-3503